StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
UPDATE: Intercept Pharma (ICPT) Changes Main Goal in Phase Three Nash Study with OCA - Bloomberg
February 10, 2017 8:37 AM
(Updated - February 10, 2017 8:41 AM EST)
Intercept Pharma (NASDAQ: ICPT) said ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Trader Talk
Next Articles
Intercept (ICPT) NASH Trial Amendment Doesn't Change Probability of Success - Cantor Fitzgerald
February 10, 2017 12:39 PM
Intercept Pharmaceuticals (ICPT) Trial Amendments 'Increase Probability for Success' - Wedbush
February 10, 2017 12:31 PM
Intercept (ICPT) NASH Trial Updates Offers 'Positives and Negatives' - Baird
February 10, 2017 12:17 PM
Intercept Pharmaceuticals (ICPT) NASH Trial Changes Increase Probability of Success and Timely Approval - BMO
February 10, 2017 11:40 AM
Intercept (ICPT) NASH Trial Changes Lowers the Hurdle for Success - FBR
February 10, 2017 11:35 AM
Intercept Pharma (ICPT) Falls 10% Ahead of Update on Phase 3 Trial of OCA
February 10, 2017 8:18 AM
Intercept Pharma (ICPT) to Provide Update on Phase 3 REGENERATE Trial of OCA in NASH Today
February 10, 2017 7:05 AM
Intercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid for the Treatment of NASH Patients with Liver Fibrosis
February 10, 2017 7:00 AM
